Press releasePRNewswire
Castle Biosciences
CSTL · NASDAQ
$33.15+$0.985 (+3.06%)TodayMarket closed ·
Prev close $32.17
Latest news
- Press releasePRNewswire
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
- Press releasePRNewswire
Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management
- Press releasePRNewswire
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
- Press releasePRNewswire
New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™
- Press releasePRNewswire
Castle Biosciences to Open New Laboratory Facility in Scottsdale
- Press releasePRNewswire
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
- Press releasePRNewswire
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
- Press releasePRNewswire
SciBase receives additional order from Castle Biosciences, advancing the collaboration
- Press releasePRNewswire
Castle Biosciences to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
Castle Biosciences Q2 Adj. EPS $(0.07) Beats $(0.41) Estimate, Sales $103.546M Beat $86.240M Estimate
- Press releasePRNewswire
Castle Biosciences Reports Second Quarter 2026 Results
- Press releasePRNewswire
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
- Press releasePRNewswire
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test
- Press releasePRNewswire
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
- News
Castle Biosciences Announces Published Study In 'Dermatology And Therapy' Showing DecisionDx-Melanoma Test Outperforms MIA Nomogram In Predicting Sentinel Lymph Node Positivity Risk
- Press releasePRNewswire
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
- Press releasePRNewswire
Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
- Press releasePRNewswire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus
- Press releasePRNewswire
Castle Biosciences to Present at the 2026 Jefferies Global Healthcare Conference
- Press releasePRNewswire
Castle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation
- News
Earnings Scheduled For May 6, 2026
- Press releasePRNewswire
Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month
- Press releasePRNewswire
New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus
- Press releasePRNewswire
Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS
- Press releasePRNewswire
Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026
- News
Expert Outlook: Castle Biosciences Through The Eyes Of 6 Analysts
- News
Castle Biosciences Q4 Earnings Assessment
- News
Castle Biosciences Q4 Adj. EPS $(0.08) Beats $(0.29) Estimate, Sales $87.010M Beat $79.048M Estimate
- Press releaseGlobe Newswire
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
- News
Earnings Scheduled For February 26, 2026
- News
Exploring Castle Biosciences's Earnings Expectations
- News
The Analyst Verdict: Castle Biosciences In The Eyes Of 7 Experts
- News
A Glimpse of Castle Biosciences's Earnings Potential
- Press releasePRNewswire
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
- Press releaseGlobe Newswire
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
- Press releaseBusiness Wire
Castle Biosciences Honored with Top Workplaces Awards
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.